GlassScriptPhysician profile
Nihar N Shah
NPI 1356605018
$5,232.02
in general payments reported to CMS, 2019-2025
30 companies · $550 in 2025
The $550 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $484 · 2021: $341 · 2022: $580 · 2023: $495 · 2024: $2,259 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796 · Travel and Lodging: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.91 |
| Travel and Lodging | $1,508.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,724.52 | 2019-2025 | Apollo Esg System, Overstitch Endoscopic Suturing System |
| Abbvie INC. | $1,310.42 | 2019-2025 | Skyrizi, Mavyret, Rinvoq |
| Apollo Endosurgery US INC | $302.77 | 2021 | |
| Endogastric Solutions, INC | $247.96 | 2022-2023 | Esophyx |
| Stryker Corporation | $177.00 | 2020 | |
| Merit Medical Systems INC | $161.41 | 2024 | Endomaxx Stent and Delivery System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.50 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $130.98 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $120.02 | 2019-2025 | Eohilia |
| Medtronic, INC. | $119.79 | 2025 | Endoflip |
| Ironwood Pharmaceuticals, INC | $102.62 | 2019-2024 | |
| Celgene Corporation | $93.48 | 2022-2023 | Zeposia |
| 3-D Matrix, INC. | $83.93 | 2024 | |
| Braintree Laboratories, INC. | $61.43 | 2020-2024 | Sutab, Suflave |
| Ardelyx, INC. | $59.23 | 2024-2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $46.89 | 2024-2025 | Vegzelma |
| Genzyme Corporation | $43.36 | 2025 | |
| Gilead Sciences, INC. | $34.13 | 2020-2022 | |
| Dova Pharmaceuticals | $32.85 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $29.61 | 2023 | Fujifilm |
| Shire North American Group INC | $27.42 | 2019 | |
| Allergan, INC. | $25.77 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $22.25 | 2024 | Terlivaz |
| Romark Laboratories, Lc | $21.26 | 2019-2020 | |
| Amgen INC. | $21.06 | 2025 | Uplizna |
| Phathom Pharmaceuticals, INC. | $19.66 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $19.11 | 2025 | Vowst |
| Pharming Healthcare, INC. | $19.08 | 2021 | |
| Pfizer INC. | $15.92 | 2025 | |
| Merck Sharp & Dohme LLC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nihar Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.